title: Radiofrequency catheter ablation of sustained ventricular tachycardia in idiopathic dilated cardiomyopathy.
abstract: BACKGROUND
  The feasibility of radiofrequency (RF) catheter ablation for the treatment of sustained ventricular tachycardia (VT) in patients with coronary artery disease and remote myocardial infarction has recently been demonstrated. At present, therapeutic options for VT in patients with idiopathic dilated cardiomyopathy (DCM) include antiarrhythmic drugs and implantable cardioverter/defibrillators (ICD). The purpose of the present study was to investigate the feasibility of RF catheter ablation in patients with idiopathic DCM who could not be adequately treated by conventional treatment modalities because of incessant or frequent, recurrent VT.
  
  
  RESULTS
  RF current application for ablation of 9 VTs (mean cycle length, 402 +/- 78 ms) was attempted in 8 patients with idiopathic DCM (4 men, 4 women; mean age, 54 +/- 6 years; mean left ventricular ejection fraction, 30 +/- 9%). Inclusion criteria for ablation were incessant VT (n = 4) or frequent, recurrent VT reproducibly inducible with programmed electrical stimulation (n = 5). Three patients had suffered aborted sudden cardiac death, and 2 had experienced syncope. Two patients were artificially ventilated and catecholamine dependent for hemodynamic reasons at the time of attempted ablation. Potential target sites for RF current application were identified by detailed endocardial mapping during sinus rhythm, activation and entrainment mapping during VT, and pace mapping. After 7 +/- 5 RF pulses (range, 2 to 18 pulses; median, 6 pulses) applied with 32 +/- 7 W for 39 +/- 9 seconds, 6 of the 9 target VTs (67%) were rendered noninducible (4 of 4 incessant VTs and 2 of 5 chronic recurrent VTs). In 6 patients, VTs with ECG morphologies other than the target VTs were inducible after RF catheter ablation. Seven patients were on antiarrhythmic drugs during the ablation procedure and during the follow-up period of 8 +/- 5 months (range, 2 to 17 months). One patient received an ICD before RF ablation, 4 patients after RF ablation, and 1 patient after ablation of an incessant VT and before attempted ablation of frequent, recurrent VTs. One patient underwent heart transplantation 5 months after ablation in end-stage heart failure. There were no acute complications during the mapping and ablation procedure. During the follow-up period, 1 patient had been resuscitated from ventricular fibrillation 6 weeks after ablation and finally died of congestive heart failure 2 weeks later. No further episodes of incessant VT occurred in the patients who had undergone RF current application for ablation of incessant VT. A complete prevention of VT could be achieved in 2 of 8 patients, whereas in 5 patients, VT episodes were stored in the ICD devices during follow-up.
  
  
  CONCLUSIONS
  The results of the present study indicate that RF current application for ablation of VT in a select group of patients with idiopathic DCM is feasible. The efficacy of RF ablation may be high in patients presenting with incessant VT, whereas the success rate seems to be only moderate in patients with chronic recurrent VT. In all patients, additional treatment options, including antiarrhythmic drugs, ICDs, and/or heart transplantation, were applied after RF ablation, indicating that RF ablation for this indication may be an adjunctive and not a curative treatment option.
authors.affiliation: Hospital of the Westfälische Wilhelms-University, Department of Cardiology and Angiology, Münster, Germany.
authors.forename: H
authors.initials: H
authors.lastname: Kottkamp
authors.forename: G
authors.initials: G
authors.lastname: Hindricks
authors.forename: X
authors.initials: X
authors.lastname: Chen
authors.forename: J
authors.initials: J
authors.lastname: Brunn
authors.forename: S
authors.initials: S
authors.lastname: Willems
authors.forename: W
authors.initials: W
authors.lastname: Haverkamp
authors.forename: M
authors.initials: M
authors.lastname: Block
authors.forename: G
authors.initials: G
authors.lastname: Breithardt
authors.forename: M
authors.initials: M
authors.lastname: Borggrefe
mesh_terms: D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D002304:Cardiac Pacing, Artificial; D002311:Cardiomyopathy, Dilated / Q000150:complications* / Q000503:physiopathology; D017115:Catheter Ablation; D017147:Defibrillators, Implantable; D004562:Electrocardiography; D005240:Feasibility Studies; D005260:Female; D005500:Follow-Up Studies; D006329:Heart Conduction System / Q000503:physiopathology / Q000601:surgery; D006801:Humans; D008297:Male; D008875:Middle Aged; D017180:Tachycardia, Ventricular / Q000209:etiology / Q000503:physiopathology / Q000601:surgery* / Q000628:therapy; D013997:Time Factors
chemical_list: D000889:Anti-Arrhythmia Agents